Randomized phase II study of docetaxel followed by vandetanib (ZD6474) vs. docetaxel plus vandetanib in patients with persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma

eagle-i ID

Resource Type

Properties

1. ClinicalTrials.gov url

   http://www.clinicaltrials.gov/ct2/show/NCT00872989?term=S0904&rank=1

2. Intervention

   Docetaxel

3. Intervention

   Vandetanib

4. Resource Description

   RATIONALE: Vandetanib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. It is not yet known whether docetaxel is more effective when given alone or together with vandetanib. PURPOSE: This randomized phase II trial is studying docetaxel given together with or without vandetanib to see how well it works in treating patients with persistent or recurrent ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cancer.

5. Contact

   Berenberg, Jeffrey

6. PI

   Berenberg, Jeffrey

7. Topic

   ovarian cancer

8. Study Population

   Females age 18 and older with histologically confirmed ovarian epithelial, fallopian tube, or primary peritoneal carcinoma.

9. Funded by

   SWOG

10. Phase

    Phase 2 clinical trial

11. Performed by

    Clinical Protocol & Data Management Shared Resource